Pfizer and Valneva to seek approval for Lyme disease vaccine despite phase 3 trial missing primary endpoint

Pfizer and Valneva reported that their phase 3 Lyme disease vaccine trial did not meet its primary endpoint, attributing the shortfall to fewer than expected Lyme disease cases during the study.